Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20248043 | 0.86 | L3MBTL3 (0.51) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL24747253 | 0.84 | VNN1 (0.42) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL23107822 | 0.83 | MAPT (0.44) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL9853734 | 0.82 | MAPT (0.50) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL17664587 | 0.81 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2POLBRAB9A | |
| SCHEMBL16440176 | 0.81 | HSD11B1 (0.51) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL9881494 | 0.81 | MAPT (0.53) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL29576618 | 0.81 | MAPT (0.53) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL22523820 | 0.80 | MAPT (0.56) | MAPTALDH1A1KDM4EMEN1HTT | |
| SCHEMBL82236 | 0.79 | MAPT (0.50) | MAPTALDH1A1KDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | MAPT 3676/4885ALDH1A1 2924/4885KDM4E 2228/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885ALDH1A1 2353/4885KDM4E 1618/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | MAPT 2812/4885ALDH1A1 1722/4885KDM4E 2261/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | MAPT 1331/4885ALDH1A1 1072/4885KDM4E 3521/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885ALDH1A1 2353/4885KDM4E 1618/4885 |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | MAPT 4668/4885ALDH1A1 3958/4885KDM4E 1381/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MAPT 2745/4885ALDH1A1 1560/4885KDM4E 572/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | MAPT 3629/4885ALDH1A1 337/4885KDM4E 2919/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | MAPT 1331/4885ALDH1A1 1072/4885KDM4E 3521/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | MAPT 103/4885ALDH1A1 1020/4885KDM4E 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.